Fourteen immunosuppressed patients with Pneumocystis carinii infection presented in two clusters that were separated by 2 years. The diagnosis in all cases was made early by alveolar lavage with cytology. The first group of seven patients was immunosuppressed with cyclophosphamide or azathioprine and prednisolone. All recovered with high dose co-trimoxazole. The second group of seven patients was on prednisolone and cyclosporin A. Despite identical treatment three patients died and a further two who survived lost their grafts from rejection. Our data suggest that cyclosporin A adversely affects the prognosis from Pneumocystis carinii infection and raises the question of prophylactic co-trimoxazole in these patients. The clustering of Pneumocystis carinii infection suggests the possibility of nosocomial transmission although in this study we were unable to implicate person-to-person spread of infection.
Introduction
Pneumocystis carinii is a well documented cause of atypical pneumonia in immunocompromised patients. The incidence of P. carinii has been reported to be less than 1% in renal transplant patients.1 More recently this incidence has been reported to be as high as 9% in renal transplant patients receiving cyclosporin A and prednisolone immunosuppression. 2 The origin of P. carinii infection remains uncertain. It is generally accepted that most cases are due to re-activation of latent organisms present in patients' lungs. Reports of clusters or outbreaks make direct person-to-person or nosocomial transmission a distinct possibility although conclusive evidence for this is lacking. The present report describes a clustering phenomenon and a poor prognosis in patients receiving immunosuppression with cyclosporin A.
Patients and methods
Fourteen patients with Pneumocystis carinii pneumonia are described. Clinical details of patients are shown in Tables I and II. The first group of  patients (Table I) was being treated with azathioprine (2-2.5 mg/kg/day) or cyclophosphamide (2- 3mg/kg/day) adjusted according to the leucocyte count and the second group (Table II) Patients, particularly those receiving cyclosporin A treatment, tended to follow a similar clinical course. The first presenting symptom was dyspnoea alone occurring over 3 to 14 days. On admission the chest X-ray was normal or showed non-specific bilateral radiographic shadowing in the lower lobes, confluent shadowing developed radiographically over the next few days. Hypoxia (P02 5.6-9.0 kPa) was either present or developed soon after admission. In the second group only three patients were pyrexial and they all survived.
The two groups of patients each presented within a period of 12 could be identified except the need for mechanical ventilation, which reflects the severity of the lung lesion.
We still consider co-trimoxazole to be the treatment of choice in pneumocystis pneumonia. Therapeutic serum levels are more reliably obtained using the i.v. route and low serum sulphonamide and trimethoprim concentrations following oral administration have been reported." Chemoprophylaxis with co-trimoxazole has been shown to be effective. 12 However, it is a bacteriostatic rather than a bacteriocidal drug against P. carinii'3 making the patient prone to infection once prophylaxis is stopped.'4 There is also a theoretical risk of resistant strains emerging during prophylaxis and synergistic nephrotoxicity with cyclosporin A has been reported. The diagnosis of P. carinii infection is often difficult. We established a rapid diagnosis in all 14 patients using cytology of alveolar fluid.3 Clinical suspicion of P. carinii infection must be high even though the signs are variable. Classic radiographic abnormalities of diffuse infiltrates and alveolar shadowing are not a consistent finding in P. carinii infection.'5 The severity of the disease could not be accurately assessed radiologically. Pyrexia was also an unreliable indicator of infection particularly in those patients receiving cyclosporin A. The only consistent finding was hypoxia (Po2 4.5-9.3 kPa) which was also found in the six patients reported by Ballardie et al. 5 All six patients in their series recovered; however, none were currently using cyclosporin A for immunosuppression.
Our data suggest that cyclosporin A increases the incidence and adversely affects the prognosis of immunocompromised patients with P. carinii infection despite prompt diagnosis and treatment with high dose co-trimoxazole.
